Biological agents are highly effective in preventing or minimizing disability in multiple sclerosis, though access in resource-limited countries is limited by social and structural determinants.
Highlights the need for financial support mechanisms to improve access to biologic disease-modifying therapies for multiple sclerosis in resource-limited countries.
Biological agents are highly effective in preventing/minimizing disability related to multiple sclerosis. However, in resource-limited countries, the diagnosis and management of multiple sclerosis are limited by social and structural determinants of health. Support for patients to access these medicines through government schemes or insurance coverage is important in preventing disability.
Nazneen et al. (2025) studied this question. Biological agents are highly effective in preventing or minimizing disability in multiple sclerosis, though access in resource-limited countries is limited by social and structural determinants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: